nach oben

Endocrine

Erschienen in:

16.12.2016 | Review

The emergence of levothyroxine as a treatment for hypothyroidism

verfasst von: James V. Hennessey

Erschienen in: Endocrine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To describe the historical refinements, understanding of physiology and clinical outcomes observed with thyroid hormone replacement strategies.

Methods

A Medline search was initiated using the search terms, levothyroxine, thyroid hormone history, levothyroxine mono therapy, thyroid hormone replacement, combination LT4 therapy, levothyroxine Bioequivalence. Pertinent articles of interest were identified by title and where available abstract for further review. Additional references were identified in the course of review of the literature identified.

Results

Physicians have intervened in cases of thyroid dysfunction for more than two millennia. Ingestion of animal thyroid derived preparations has been long described but only scientifically documented for the last 130 years. Refinements in hormone preparation, pharmaceutical production and regulation continue to this day. The literature provides documentation of physiologic, pathologic and clinical outcomes which have been reported and continuously updated. Recommendations for effective and safe use of these hormones for reversal of patho-physiology associated with hypothyroidism and the relief of symptoms of hypothyroidism has documented a progressive refinement in our understanding of thyroid hormone use. Studies of thyroid hormone metabolism, action and pharmacokinetics have allowed evermore focused recommendations for use in clinical practice. Levothyroxine mono-therapy has emerged as the therapy of choice of all recent major guidelines.

Conclusions

The evolution of thyroid hormone therapies has been significant over an extended period of time. Thyroid hormone replacement is very useful in the treatment of those with hypothyroidism. All of the most recent guidelines of major endocrine societies recommend levothyroxine mono-therapy for first line use in hypothyroidism.

E.C. Kendall, The isolation in crystalline form of the compound containing iodin, which occurs in the thyroid: its chemical nature and physiologic activity. J. Am. Med. Assoc. 64, 2042–2043 (1915)CrossRef

C.R. Harington, G. Barger, Chemistry of thyroxine: constitution and synthesis of thyroxine. Biochem. J. 21(1), 169–183 (1927)PubMedPubMedCentralCrossRef

C.R. Harington, Chemistry of thyroxine: constitution and synthesis of desiodo-thyroxine. Biochem. J. 20(2), 300–313 (1926)PubMedPubMedCentralCrossRef

B. Biondi, L. Wartofsky, Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J. Clin. Endocrinol. Metab. 97(7), 2256–2271 (2012). doi:10.1210/jc.2011-3399 PubMedCrossRef

J. Gross, R. Pitt-Rivers, The identification of 3:5:3′-L-triiodothyronine in human plasma. Lancet 1(6705), 439–441 (1952). doi:S0140-6736(52)91952-1PubMedCrossRef

J. Gross, R. Pitt-Rivers, 3:5:3′ -triiodothyronine. 1. Isolation from thyroid gland and synthesis. Biochem. J. 53(4), 645–650 (1953)PubMedPubMedCentralCrossRef

J. Roche, S. Lissitzky, R. Michel, The metabolism of triiodothyronin and its biosynthesis as a thyroid hormone. C. R. Seances Soc. Biol. Fil. 146(19-20), 1474–1477 (1952)PubMed

L.E. Braverman, S.H. Ingbar, K. Sterling, Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J. Clin. Invest 49, 855–864 (1970)PubMedPubMedCentralCrossRef

A.C. Bianco, D. Salvatore, B. Gereben, M.J. Berry, P.R. Larsen, Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 23(1), 38–89 (2002)PubMedCrossRef

10.

J. Jonklaas, B. Davidson, S. Bhagat, S. SJ, : Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 299(7), 769–777 (2008)PubMedCrossRef

11.

A. Pilo, G. Iervasi, F. Vitek, M. Ferdeghini, F. Cazzuola, R. Bianchi, Thyroidal and peripheral production of 3,5,3′-triiodothyronine in humans by multicompartmental analysis. Am J. Physiol. 258(4 Pt 1), E715–726 (1990)PubMed

12.

S. Snyder, R.E. Listecki, Bioidentical thyroid replacement therapy in practice: Delivering a physiologic T4:T3 ratio for improved patient outcomes with the Listecki-Snyder protocol. Int. J. Pharm. Compd. 16(5), 376–380 (2012)PubMed

13.

S. Slater, The discovery of thyroid replacement therapy. Part 3: a complete transformation. J. R. Soc. Med. 104(3), 100–106 (2011). doi:10.1258/jrsm.2010.10k052 PubMedPubMedCentralCrossRef

14.

F. Semon, In discussion of ‘A typical case of myxedema’. In: Drewitt, F.D. (ed.) Proceedings of the Clinical Society of London, London, GB 1883, Vol. ii, pp. 1072–1074. BMJ

15.

C.T. Sawin, The invention of thyroid therapy in the late nineteenth century. Endocrinol. 11(1), 1–3 (2001)CrossRef

16.

Report on myxoedema. In, vol. Suppl 1. Transactions of the clinical society of London, (1888)

17.

R. Bettencourt, S. J-A, Un cas de myxoedeme traite par la greffe hypodermique du corps thyroide d’um mouton. La. Sem. Med. 1884(10), 294 (1890)

18.

R. Bettencourt, J.-A. Serrano, Un cas de myxoedeme (cachexie pachydermique) traite par la greffe hypodermique du corps thyroide d’um mouton. In: l’Association Francaise puor l’Advancement des Sciences, Limoges 1890, pp. 683–690 (1891)

19.

A.M. Bettencourt-Rodrigues. Communicacoes scientificas. In: C.b. Sawin (ed.) Lisbon Society of Medical Sciences. J. Soc. Sci. Med. Lisboa, Lisbon, p. 114 (1890)

20.

G.R. Murray, Note on the treatment of Myxoedema by hypodermic injections of an extract of the thyroid gland of a sheep. British Medical Association. (BMJ, Bournemouth), p. 796 (1891)

21.

G.R. Murray, Remarks on the treatment of myxedema with thyroid juice, with notes on four cases. In: 60th Annual Meeting of the British Medical Association 1892, pp. 449–451. BMJ

22.

S. Slater, The discovery of thyroid replacement therapy. Part 2: the critical 19th century. J. R. Soc. Med. 104(2), 59–63 (2011). doi:10.1258/jrsm.2010.10k051 PubMedPubMedCentralCrossRef

23.

H.W.G. Mackenzie, A case of myxedema treated with great benefit by feeding with fresh thyroid glands. BMJ 1892(ii), 940–941 (1892)CrossRef

24.

G.R. Murray, The life-history of the first case of myxedema treated by thyroid extract. BMJ 1920(i), 359–360 (1920)CrossRef

25.

E.L. Fox, A case of myxoedema treated by taking extract of thyroid by mouth. Br. Med. J. 2, 941 (1892)PubMedPubMedCentralCrossRef

26.

H.W.G. Mackenzie, A case of myxoedema treated with great benefit by feeding with fresh thyroid glands. Br. Med. J. 2 (1892)

27.

B. Bramwell, The thyroid treatment of myxoedema and sporatic cretinism, with notes of twenty-three cases of myxoedema and five cases of sporadic cretinism, treated by thyroid extract. Edinburgh Hosp. Rep. 1895(3), 116–249 (1895)

28.

H.A. Selenkow, M.S. Wool, A. New, Synthetic thyroid hormone combination for clinical therapy. Ann. Intern. Med. 67(1), 90–99 (1967)CrossRef

29.

G.J. Canaris, J.F. Steiner, E.C. Ridgway, Do traditional symptoms of hypothyroidism correlate with biochemical disease? J. Gen. Intern. Med. 12(9), 544–550 (1997)PubMedPubMedCentralCrossRef

30.

G.J. Canaris, N.R. Manowitz, G.H. Mayor, E.C. Ridgway, The colorado thyroid disease prevalence study. Arch. Intern. Med. 160(4), 526–534 (2000)PubMedCrossRef

31.

A. Carle, I.B. Pedersen, N. Knudsen, H. Perrild, L. Ovesen, P. Laurberg, Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case-control study. Eur. J. Endocrinol. 171(5), 593–602 (2014). doi:10.1530/EJE-14-0481 PubMedCrossRef

32.

S. Taylor, M. Kapur, R. Adie, Combined thyroxine and triiodothyronine for thyroid replacement therapy. Br. Med. J. 2(5704), 270–271 (1970)PubMedPubMedCentralCrossRef

33.

R.F. Farquharson, A.H. Squires, Inhibition of secretrion of thyroid gland by continued ingestion of thyroid substance. Tr. Am. Phys. 56, 87–97 (1941)

34.

M.A. Greer, The effect on endogenous thyroid activity of feeding desiccated thyroid to normal human subjects. N. Engl. J. Med. 244(11), 385–390 (1951). doi:10.1056/NEJM195103152441101 PubMedCrossRef

35.

L.E. Braverman, S.H. Ingbar, Anomalous effects of certain preparations of desiccated thyroid on serum protein-bound iodine. N. Engl. J. Med. 270, 439–442 (1964). doi:10.1056/NEJM196402272700903 PubMedCrossRef

36.

E.A. Novak, J.M. Holthaus, R.O. Ogborn, Clinical study of levo-thyroxine and aged desiccated thyroid in euthyroid subjects. Am. J. Med. Sci. 247, 336–343 (1964)PubMedCrossRef

37.

P. Starr, Hormone content of desiccated thyroid. JAMA 205(5), 313–314 (1968)PubMedCrossRef

38.

A.G. Macgregor, Why does anybody use thyroid B.P.?. Lancet 1(7172), 329–332 (1961)PubMedCrossRef

39.

P.B. Fowler, Thyroid extract. Br. Med. J. 2(6144), 1089 (1978)PubMedPubMedCentralCrossRef

40.

M.I. Surks, A.R. Schadlow, J.H. Oppenheimer, A new radioimmunoassay for plasma L-triiodothyronine: measurements in thyroid disease and in patients maintained on hormonal replacement. J. Clin. Invest. 51(12), 3104–3113 (1972). doi:10.1172/JCI107137 PubMedPubMedCentralCrossRef

41.

J. Chalmers, G. Dickson, J. Elks, et al. The synthesis of thyroxine and related substances. Part V. A synthesis of L-thyroxine from l-tyrosine. J. Chem. Soc. 3424–3422 (1949)

42.

Drugbank: DrugBank: Levothyroxine. http://www.drugbank.ca/drugs/DB00451 (2016). Accessed 21 Jun 2005

43.

B.A. Sachs, L. Wolfman, G. Murthy, Lipid and clinical response to a new thyroid hormone combination. Am. J. Med. Sci. 256(4), 232–238 (1968)PubMedCrossRef

44.

R.N. Smith, S.A. Taylor, J.C. Massey, Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism. Br. Med. J. 4(5728), 145–148 (1970)PubMedPubMedCentralCrossRef

45.

I.M. Jackson, W.E. Cobb, Why does anyone still use desiccated thyroid USP? Am. J. Med. 64(2), 284–288 (1978)PubMedCrossRef

46.

R. Penny, S.D. Frasier, Elevated serum concentrations of triiodothyronine in hypothyroid patients. Values for patients receiving USP thyroid. Am. J. Dis. Child 134(1), 16–18 (1980)PubMedCrossRef

47.

M.S. LeBoff, M.M. Kaplan, J.E. Silva, P.R. Larsen, Bioavailability of thyroid hormones from oral replacement preparations. Metabolism. 31(9), 900–905 (1982)PubMedCrossRef

48.

A. Lev-Ran, Part-of-the-day hypertriiodothyroninemia caused by desiccated thyroid. JAMA 250(20), 2790–2791 (1983)PubMedCrossRef

49.

S.R. Smith, Desiccated thyroid preparations. Obsolete therapy. Arch. Intern. Med. 144(5), 926–927 (1984)PubMedCrossRef

50.

C.T. Sawin, A. Geller, J.M. Hershman, W. Castelli, P. Bacharach, The aging thyroid. The use of thyroid hormone in older persons. JAMA 261(18), 2653–2655 (1989)PubMedCrossRef

51.

K. Petersen, C. Bengtsson, L. Lapidus, G. Lindstedt, E. Nystrom, Morbidity, Mortality and quality of life for patients treated with levothyroxine. Arch. Intern. Med. 150(10), 2077–2081 (1990)PubMedCrossRef

52.

G. Mercuro, M.G. Panzuto, A. Bina, M. Leo, R. Cabula, L. Petrini, F. Pigliaru, S. Mariotti, Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J. Clin. Endocrinol. Metab. 85(1), 159–164 (2000)PubMedCrossRef

53.

J.V. Hennessey, K.D. Burman, L. Wartofsky, The equivalency of two L-Thyroxine preparations. Ann. Intern. Med. 102, 770–773 (1985)PubMedCrossRef

54.

J.M. Stock, M.I. Surks, J.H. Oppenheimer, Replacement dosage of L-thyroxine in hypothyroidism. A re-evaluation. N. Engl. J. Med. 290(10), 529–533 (1974). doi:10.1056/NEJM197403072901001 PubMedCrossRef

55.

M. Maeda, N. Kuzuya, Y. Masuyama, Y. Imai, H. Ikeda, Changes in serum triiodothyronine, thyroxine, and thyrotropin during treatment with thyroxine in severe primary hypothyroidism. J. Clin. Endocrinol. Metab. 43(1), 10–17 (1976). doi:10.1210/jcem-43-1-10 PubMedCrossRef

56.

R.L. Rosenbaum, U.S. Barzel, Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann. Intern. Med. 96(1), 53–55 (1982)PubMedCrossRef

57.

C.T. Sawin, T. Herman, M.E. Molitch, M.H. London, S.M. Kramer, Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am. J. Med. 75(2), 206–209 (1983)PubMedCrossRef

58.

I.E. Brajkovich, K. Mashiter, G.F. Joplin, J. Cassar, Serum T4, T3, and TSH levels in primary hypothyroidism during replacement therapy with thyroxine. Metabolism 32(8), 745–747 (1983). doi:0026-0495(83)90101-4PubMedCrossRef

59.

F.B. Davis, R.S. LaMantia, S.W. Spaulding, R.E. Wehmann, P.J. Davis, Estimation of a physiologic replacement dose of levothyroxine in elderly patients with hypothyroidism. Arch. Intern. Med. 144(9), 1752–1754 (1984)PubMedCrossRef

60.

J.V. Hennessey, J.E. Evaul, Y.-C. Tseng, K.D. Burman, L. Wartofsky, L-thyroxine dosage: A reevaluation of therapy with contemporary preparations. Ann. Intern. Med. 105, 11–15 (1986)PubMedCrossRef

61.

L.H. Fish, H.L. Schwartz, J. Cavanaugh, M.W. Steffes, J.P. Bantle, J.H. Oppenheimer, Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. N. Engl. J. Med. 316, 764–770 (1987)PubMedCrossRef

62.

J.V. Hennessey, L. Wartofsky, Thyroxine preparations. Ann. Intern. Med. 101(1), 140 (1984)CrossRef

63.

C.T. Sawin, M.I. Surks, M. London, R. Chingleput, P.R. Larsen, Oral thyroxine: variation in biologic action and tablet content. Ann. Intern. Med. 100, 641–645 (1984)PubMedCrossRef

64.

J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22(12), 1200–1235 (2012). doi:10.1089/thy.2012.0205 PubMedCrossRef

65.

J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B. Kim, R. Peeters, M.S. Rosenthal, A. Sawka, Guidelines for the treatment of hypothyroidism. Thyroid (2014). doi:10.1089/thy.2014.0028

66.

J.V. Hennessey, Levothyroxine a new drug? Since when? How could that be?. Thyroid 13(3), 279–282 (2003)PubMedCrossRef

67.

J.V. Hennessey, Historical and current perspective in the use of thyroid extracts for the treatment of hypothyroidism. Endocr. Pract. 21(10), 1161–1170 (2015). doi:10.4158/EP14477.RA PubMedCrossRef

68.

D.A. Escalante, N. Arem, R. Arem, Assessment of interchangeability of two brands of levothyroxine preparations with a third-generation TSH Assay. Am. J. Med. 98, 374–378 (1995)PubMedCrossRef

69.

R.W. Rees-Jones, A.R. Rolla, P.R. Larsen, Hormonal content of thyroid replacement preparations. JAMA 243(6), 549–550 (1980)PubMedCrossRef

70.

B.J. Dong, V.R. Young, B. Rapoport, The nonequivalence of levothyroxine products. Drug Intell. Clin. Pharm. 20, 77–78 (1986)PubMed

71.

S.S. Stoffer, W.E. Szpunar, Potency of current levothyroxine preparations evaluated by high-performance liquid chromatography. Henry Ford Med. J 36(1), 64–65 (1988)

72.

J.M. Jacobsen, A. Ramos-Gabatin, R.L. Young, S.G. Watkins, M.L. Brown, Nonequality of brand name thyroxine products. JAMA 243(8), 733 (1980)CrossRef

73.

A. Ramos-Gabatin, J.M. Jacobson, R.L. Young, In vivo comparison of Levothyroxine preparations. JAMA 247(2), 203–205 (1982)PubMedCrossRef

74.

N. Lowy, Regulatory Issues regarding slow release T3, extracts, and compunded T4/T3. Paper presented at the Treatment of Hypothyroidism; Exploring the Possibilities, Westin City Center, Washington DC, 25 April 2013

75.

Docket Number 97N-0314, Prescription drug products; levothyroxine sodium. Fed. Regist. 62(157), 43535–43538 (1997)

76.

Guidance for industry: Levothyroxine sodium tablets- In vivo pharmacokinetic and bioavailability studies and invitro dissolution testing. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 1–8 (2000)

77.

Guidance for Industry: Levothyroxine Sodium Products Enforcement of August 14, 2001; Compliance Date and Submission of New Applications.: In: U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). pp. 1–6. (2001)

78.

Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products- General Considerations (Draft Guidance). (2002)

79.

V.A. Blakesley, W. Awni, C. Locke, T. Ludden, G.R. Granneman, L.E. Braverman, Are bioequivalalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?. Thyroid 14(3), 191–200 (2004)PubMedCrossRef

80.

Tiche Softgel. http://www.thyroidcollection.net/cont/download.asp?u=21 (2016)

81.

C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine (2016). doi:10.1007/s12020-016-1035-1

82.

D. Pabla, F. Akhlaghi, H. Zia, A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur. J. Pharm. Biopharm. 72(1), 105–110 (2009). doi:10.1016/j.ejpb.2008.10.008 PubMedCrossRef

83.

M.G. Santaguida, C. Virili, S.C. Del Duca, M. Cellini, I. Gatto, N. Brusca, C. De Vito, L. Gargano, M. Centanni, Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49(1), 51–57 (2015). doi:10.1007/s12020-014-0476-7 PubMedCrossRef

84.

R. Vita, S. Benvenga, Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. Endocr. Pract. 20(3), e38–41 (2014). doi:10.4158/EP13316.CR PubMedCrossRef

85.

P.J. Kim, I. Sachmechi, Levothyroxine malabsorption induced by diabetic gastroparesis exacerbated during pregnancies: effect of intramuscular levothyroxine injections and levothyroxine soft gel capsules. AACE Clin. Case Rep. 1, e73–e78 (2015)CrossRef

86.

R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43(1), 154–160 (2013). doi:10.1007/s12020-012-9772-2 PubMedCrossRef

87.

T.M. Grant, T. Zhu, C. Brandquist, N.S. Teuscher, M.J. Lamson, Randomized, open-label, single-dose, two-way crossover study to determine the relative bioavailability of a reformulated levothyroxine tablet compared with the commercial tablet (levoxyl(R)) in healthy volunteers. Clin. Pharmacol. Ther. 85(Suppliment 1), S95 (2009). PIII-85

88.

P. Colucci, P. D’Angelo, G. Mautone, C. Scarsi, M.P. Ducharme, Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther Drug Monit 33(3), 355–361 (2011). doi:10.1097/FTD.0b013e318217b69f PubMedCrossRef

89.

J.V. Hennessey, The FDA revises requirements for levothyroxine products. Thyroid 18(5), 487–490 (2008)PubMedCrossRef

90.

J.V. Hennessey, A.O. Malabanan, B.R. Haugen, E.G. Levy, Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the american thyroid association, american association of clinical endocrinologists, and the endocrine society. Endocr. Pract. 16(3), 357–370 (2010)PubMedCrossRef

91.

D.S. Ross, G.H. Daniels, D. Gouveia, The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J. Clin. Endocrinol. Metab 71(3), 764–769 (1990)PubMedCrossRef

92.

L. Somwaru, A.M. Arnold, N. Joshi, L.P. Fried, A.R. Cappola, High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women Aged 65 and Over. J. Clin. Endocrinol. Metab. 94(4), 1342–1345 (2009)PubMedPubMedCentralCrossRef

93.

J.J. Diez, Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J. Gerontol. A Biol. Sci. Med. Sci. 57(5), M315–320 (2002)PubMedCrossRef

94.

J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, Serum TSH, T4, and Thyroid Antibodies in the United States Population(1988 to 1994): National Health and Nutrition Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)PubMedCrossRef

95.

J.V. Parle, J.A. Franklyn, K.W. Cross, S.R. Jones, M.C. Sheppard, Thyroxine prescription in the community: serun thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br. J. Gen. Pract. 43(368), 107–109 (1993)PubMedPubMedCentral

96.

R.W. Flynn, S.R. Bonellie, R.T. Jung, T.M. MacDonald, A.D. Morris, G.P. Leese, Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J. Clin. Endocrinol. Metab. 95(1), 186–193 (2010). doi:10.1210/jc.2009-1625 PubMedCrossRef

97.

J.S. Mammen, J. McGready, R. Oxman, C.W. Chia, P.W. Ladenson, E.M. Simonsick, Thyroid hormone therapy and risk of thyrotoxicosis in community-resident older adults: findings from the baltimore longitudinal study of aging. Thyroid 25(9), 979–986 (2015). doi:10.1089/thy.2015.0180 PubMedPubMedCentralCrossRef

98.

D.J. Lips, M.T. van Reisen, V. Voigt, W. Venekamp, Diagnosis and treatment of levothyroxine pseudomalabsorption. Neth. J. Med. 62(4), 114–118 (2004)PubMed

99.

R.M. Bagattoli, M. Vaisman, J.S. Lima, L.S. Ward, Estudo de Adesao ao Tratamento do Hipotiroidismo. Arq. Braz. Endocrinol. Metab. 44(2), 483–487 (2000)

100.

F. Vaisman, C.M. Coeli, L.S. Ward, H. Graf, G. Carvalho, R. Montenegro Jr., M. Vaisman, How good is the levothyroxine replacement in primary hypothyroidism patients in Brazil? Data of a multicentre study. J. Endocrinol. Invest. 36(7), 485–488 (2013). doi:10.3275/8810 PubMed

101.

A.S. Kesselheim, N.K. Choudhry, J. Avorn, Burden of changes in generic pill appearance. Ann. Intern. Med. 161(11), 840 (2014). doi:10.7326/L14-5028-3 PubMedCrossRef

102.

J.K. Lee, K.A. Grace, A.J. Taylor, Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 296(21), 2563–2571 (2006). doi:10.1001/jama.296.21.joc60162 PubMedCrossRef

103.

K.W. Wenzel, Optimization of levothyroxine treatment. Dosage dependence on the existing parenchymal mass, age, body weight and fasting intake. Dtsch. Med. Wochenschr. 111(36), 1356–1362 (1986). doi:10.1055/s-2008-1068634 PubMedCrossRef

104.

M.J. Lamson, C.L. Pamplin, R.L. Rolleri, I. Klein, Quantitation of a substantial reduction in levothyroxine absorption by food. Thyroid 14, 876 (2004)

105.

T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94(10), 3905–3912 (2009)PubMedPubMedCentralCrossRef

106.

C.L. Perez, F.S. Araki, H. Graf, G.A. de Carvalho, Serum thyrotropin levels following levothyroxine administration at breakfast. Thyroid 23(7), 779–784 (2013). doi:10.1089/thy.2012.0435 PubMedCrossRef

107.

S.A. Irving, T. Vadiveloo, G.P. Leese, Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin. Endocrinol. (Oxf) 82(1), 136–141 (2015). doi:10.1111/cen.12559 CrossRef

108.

A. Stagnaro-Green, M. Abalovich, E. Alexander, F. Azizi, J. Mestman, R. Negro, A. Nixon, E.N. Pearce, O.P. Soldin, S. Sullivan, W. Wiersinga, Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21(10), 1081–1125 (2011). doi:10.1089/thy.2011.0087 PubMedPubMedCentralCrossRef

109.

C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97(3), E419–422 (2012). doi:10.1210/jc.2011-1851 PubMedCrossRef

110.

M. Munoz-Torres, M. Varsavsky, G. Alonso, Lactose intolerance revealed by severe resistance to treatment with levothyroxine. Thyroid 16(11), 1171–1173 (2006). doi:10.1089/thy.2006.16.1171 PubMedCrossRef

111.

M. Cellini, M.G. Santaguida, I. Gatto, C. Virili, S.C. Del Duca, N. Brusca, S. Capriello, L. Gargano, M. Centanni, Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99(8), E1454–1458 (2014). doi:10.1210/jc.2014-1217 PubMedCrossRef

112.

M. Asik, F. Gunes, E. Binnetoglu, M. Eroglu, N. Bozkurt, H. Sen, E. Akbal, C. Bakar, Y. Beyazit, K. Ukinc, Decrease in TSH levels after lactose restriction in Hashimoto’s thyroiditis patients with lactose intolerance. Endocrine 46(2), 279–284 (2014). doi:10.1007/s12020-013-0065-1 PubMedCrossRef

113.

S. Checchi, A. Montanaro, L. Pasqui, C. Ciuoli, V. De Palo, M.C. Chiappetta, F. Pacini, L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J. Clin. Endocrinol. Metab. 93(2), 465–469 (2008). doi:10.1210/jc.2007-1544 PubMedCrossRef

114.

M. Centanni, L. Gargano, G. Canettieri, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354(17), 1787–1795 (2006)PubMedCrossRef

115.

V. Fonseca, M. Thomas, A. Katrak, P. Sweny, J.F. Moorhead, Can urinary thyroid hormone loss cause hypothyroidism? Lancet 338(8765), 475–476 (1991). doi:0140-6736(91)90546-2PubMedCrossRef

116.

S. Benvenga, R. Vita, F. Di Bari, P. Fallahi, A. Antonelli, Do not forget nephrotic syndrome as a cause of increased requirement of levothyroxine replacement therapy. Eur. Thyroid J. 4(2), 138–142 (2015). doi:10.1159/000381310 PubMedPubMedCentralCrossRef

117.

J.M. Carswell, J.H. Gordon, E. Popovsky, A. Hale, R.S. Brown, Generic and brand name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. J. Clin. Endocrinol. Metab. (2013)

118.

C.J. Worell, Sandoz Introduces Levothyroxine Sodium Tablets, USP, A Bioequivalent Alternative Product to Synthroid and Levoxyl. In. Sandoz, a Novartis Company, Advertisement to Physicians, (2004)

119.

AACE, ATA, TES: Joint position Statement on the use and interchangeability of Thyroxine Products. www.thyoid.org/professionals/advocacy/04_12_08_thyroxine.html (2005). Accessed 3 Feb 2005

120.

H.M. Robertson, A.K. Narayanaswamy, O. Pereira, S.A. Copland, R. Herriot, A.W. McKinlay, J.S. Bevan, P. Abraham, Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. Thyroid 24(12), 1765–1771 (2014). doi:10.1089/thy.2013.0661 PubMedCrossRef

121.

H.T. Stelfox, S.B. Ahmed, J. Fiskio, D.W. Bates, An Evaluation of the adequacy of outpatient monitoring of thyroid replacement therapy. J. Eval. Clin. Pract. 10(4), 525–530 (2004)PubMedCrossRef

122.

J. Jonklaas, Sex and age differences in levothyroxine dosage requirement. Endocr. Pract. 16(1), 71–79 (2010)PubMedCrossRef

123.

A.A. Ismail, P.L. Walker, J.H. Barth, K.C. Lewandowski, R. Jones, W.A. Burr, Wrong biochemistry results: two case reports and observational study in 5310 patients on potentially misleading thyroid-stimulating hormone and gonadotropin immunoassay results. Clin. Chem. 48(11), 2023–2029 (2002)PubMed

124.

W.M. Wiersinga, L. Duntas, V. Fadeyev, B. Nygaard, M.P. Vanderpump, 2012 ETA guidelines: the use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur. Thyroid J. 1(2), 55–71 (2012). doi:10.1159/000339444 PubMedPubMedCentralCrossRef

125.

G. Brenta, M. Vaisman, J.A. Sgarbi, L.M. Bergoglio, N.C. Andrada, P.P. Bravo, A.M. Orlandi, H. Graf, Clinical practice guidelines for the management of hypothyroidism. Arq. Bras. Endocrinol. Metabol. 57(4), 265–291 (2013). doi:S0004-27302013000400003PubMedCrossRef

126.

E.M. Lichten, Synthetic thyroxine vs dessicated thyroid. JAMA 291(12), 1445 (2004). doi:10.1001/jama.291.12.1445-a PubMed

127.

P.S. Jellinger, Acquired hypothyroidism after switching from thyroid USP to levothyroxine. Clin. Cornerstone 7(Suppl 2), S22–24 (2005). doi:S1098-3597(05)80055-9PubMedCrossRef

128.

T.D. Hoang, C.H. Olsen, V.Q. Mai, P.W. Clyde, M.K. Shakir, Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J. Clin. Endocrinol. Metab. 98(5), 1982–1990 (2013). doi:10.1210/jc.2012-4107 PubMedCrossRef

129.

P. Saravanan, W.-F. Chau, N. Roberts, K. Vedhara, R. Greenwood, C.M. Dayan, Psychological well-being in patients on “adequate” doses of L-thyroxine: results of a large, controlled community-based questionaire study. Clin. Endocrinol. 57, 577–585 (2002)CrossRef

130.

,R. Bunevicius, G. Kazanavicius, R. Zalinkevicius, A.J. Prange, Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N. Engl. J. Med 340, 424–429 (1999)PubMedCrossRef

131.

W. Siegmund, K. Spieker, A.I. Weike, T. Giessmann, C. Modess, T. Dabers, G. Kirsch, E. Sanger, G. Engel, A.O. Hamm, M. Nauck, W. Meng, Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14: 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin. Endocrinol. (Oxf) 60(6), 750–757 (2004). doi:10.1111/j.1365-2265.2004.02050.x CrossRef

132.

H.F. Escobar-Morreale, J.I. Botella-Carretero, F. Escobar Del Ray, G. Morreale De Escobar, Review: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J. Clin. Endocrinol. Metab. 90(8), 4946–4954 (2005)PubMedCrossRef

133.

S. Grozinsky-Glasberg, A. Fraser, E. Nahshoni, A. Weizman, L. Leibovici, Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 91(7), 2592–2599 (2006)PubMedCrossRef

134.

C. Ma, J. Xie, X. Huang, G. Wang, Y. Wang, X. Wang, S. Zuo, Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl. Med. Commun. 30(8), 586–593 (2009). doi:10.1097/MNM.0b013e32832c79e0 PubMedCrossRef

Titel: The emergence of levothyroxine as a treatment for hypothyroidism
verfasst von: James V. Hennessey
Publikationsdatum: 16.12.2016
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-1199-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The emergence of levothyroxine as a treatment for hypothyroidism

Abstract

Objective

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Persistent hyperparathyroidism due to ectopic parathyroid gland

SIADH: differential diagnosis and clinical management

Certain HLA alleles are associated with stress-triggered Graves’ disease and influence its course

Premixed insulin regimens in type 2 diabetes: pros

Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients

Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin